期刊
CARCINOGENESIS
卷 41, 期 8, 页码 1104-1112出版社
OXFORD UNIV PRESS
DOI: 10.1093/carcin/bgz175
关键词
-
类别
资金
- Public Health England
- European Union FP7 EURATOM DoReMi network of excellence [249689]
- RISK-IR (Risk, Stem Cells and Tissue Kinetics-Ionising Radiation) [323267]
- National Science Centre, Poland, grant BITIMS [2015/19/B/ST6/01736]
- National Science Centre, Poland, grant SUT BKM [02/010/BKM18/0136]
Therapy-related and more specifically radiotherapy-associated acute myeloid leukaemia (AML) is a well-recognized potential complication of cytotoxic therapy for the treatment of a primary cancer. The CBA mouse model is used to study radiation leukaemogenesis mechanisms with Sfpi1/PU.1 deletion and point mutation already identified as driving events during AML development. To identify new pathways, we analysed 123 mouse radiation-induced AML (rAML) samples for the presence of mutations identified previously in human AML and found three genes to be mutated; Sfpi1 R235 (68%), Flt3-ITD (4%) and Kras G12 (3%), of which G12R was previously unreported. Importantly, a significant decrease in Sfpi1 gene expression is found almost exclusively in rAML samples without an Sfpi1 R235 mutation and is specifically associated with up-regulation of mir-1983 and mir-582-5p. Moreover, this down-regulation of Sfpi1 mRNA is negatively correlated with DNA methylation levels at specific CpG sites upstream of the Sfpi1 transcriptional start site. The down regulation of Sfpi1/PU.1 has also been reported in human AML cases revealing one common pathway of myeloid disruption between mouse and human AML where dysregulation of Sfpi1/PU.1 is a necessary step in AML development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据